MX2010002885A - Derivados de acido 1-(4-(bencilbenzamido)-bencil)-azetidin-3-carbo xilico y compuestos relacionados como moduladores de receptores de s1p para el tratamiento de trastornos inmunitarios. - Google Patents
Derivados de acido 1-(4-(bencilbenzamido)-bencil)-azetidin-3-carbo xilico y compuestos relacionados como moduladores de receptores de s1p para el tratamiento de trastornos inmunitarios.Info
- Publication number
- MX2010002885A MX2010002885A MX2010002885A MX2010002885A MX2010002885A MX 2010002885 A MX2010002885 A MX 2010002885A MX 2010002885 A MX2010002885 A MX 2010002885A MX 2010002885 A MX2010002885 A MX 2010002885A MX 2010002885 A MX2010002885 A MX 2010002885A
- Authority
- MX
- Mexico
- Prior art keywords
- compounds
- hepatitis
- disease
- treating
- receptor modulating
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 2
- 208000006454 hepatitis Diseases 0.000 abstract 2
- 231100000283 hepatitis Toxicity 0.000 abstract 2
- 102000005962 receptors Human genes 0.000 abstract 2
- 108020003175 receptors Proteins 0.000 abstract 2
- 208000009137 Behcet syndrome Diseases 0.000 abstract 1
- 206010009900 Colitis ulcerative Diseases 0.000 abstract 1
- 208000011231 Crohn disease Diseases 0.000 abstract 1
- 206010018364 Glomerulonephritis Diseases 0.000 abstract 1
- 206010018691 Granuloma Diseases 0.000 abstract 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 abstract 1
- 206010029164 Nephrotic syndrome Diseases 0.000 abstract 1
- 201000004681 Psoriasis Diseases 0.000 abstract 1
- 206010043561 Thrombocytopenic purpura Diseases 0.000 abstract 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 abstract 1
- 201000006704 Ulcerative Colitis Diseases 0.000 abstract 1
- 206010046851 Uveitis Diseases 0.000 abstract 1
- 150000001408 amides Chemical class 0.000 abstract 1
- 230000001363 autoimmune Effects 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 230000001684 chronic effect Effects 0.000 abstract 1
- 230000001434 glomerular Effects 0.000 abstract 1
- 208000007475 hemolytic anemia Diseases 0.000 abstract 1
- 208000026278 immune system disease Diseases 0.000 abstract 1
- 239000002955 immunomodulating agent Substances 0.000 abstract 1
- 229940121354 immunomodulator Drugs 0.000 abstract 1
- 206010028417 myasthenia gravis Diseases 0.000 abstract 1
- 208000009928 nephrosis Diseases 0.000 abstract 1
- 231100001027 nephrosis Toxicity 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Heart & Thoracic Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Ophthalmology & Optometry (AREA)
- Gastroenterology & Hepatology (AREA)
- Neurosurgery (AREA)
- Reproductive Health (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US99481207P | 2007-09-20 | 2007-09-20 | |
| PCT/US2008/010887 WO2009038759A2 (en) | 2007-09-20 | 2008-09-19 | 1-(4-(benzylbenzamid0) -benzyl) azetidine-3-carboxylic acid derivatives and related compounds as slp receptor modulators for the treatment of immune disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2010002885A true MX2010002885A (es) | 2010-04-01 |
Family
ID=40468694
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2010002885A MX2010002885A (es) | 2007-09-20 | 2008-09-19 | Derivados de acido 1-(4-(bencilbenzamido)-bencil)-azetidin-3-carbo xilico y compuestos relacionados como moduladores de receptores de s1p para el tratamiento de trastornos inmunitarios. |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US8080542B2 (enExample) |
| EP (1) | EP2188252B1 (enExample) |
| JP (1) | JP2010540438A (enExample) |
| AT (1) | ATE505454T1 (enExample) |
| AU (1) | AU2008302746B2 (enExample) |
| CA (1) | CA2699417A1 (enExample) |
| DE (1) | DE602008006209D1 (enExample) |
| ES (1) | ES2360929T3 (enExample) |
| MX (1) | MX2010002885A (enExample) |
| WO (1) | WO2009038759A2 (enExample) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7919519B2 (en) | 2005-11-23 | 2011-04-05 | Epix Pharmaceuticals Inc. | S1P receptor modulating compounds and use thereof |
| CA2630714C (en) | 2005-11-23 | 2014-01-14 | Epix Delaware, Inc. | S1p receptor modulating compounds and use thereof |
| US7790707B2 (en) | 2006-03-21 | 2010-09-07 | Epix Pharmaceuticals Inc. | S1P receptor modulating compounds and use thereof |
| US20090069288A1 (en) * | 2007-07-16 | 2009-03-12 | Breinlinger Eric C | Novel therapeutic compounds |
| US8080542B2 (en) | 2007-09-20 | 2011-12-20 | Amgen, Inc. | S1P receptor modulating compounds and use thereof |
| TW201000099A (en) * | 2008-06-20 | 2010-01-01 | Amgen Inc | S1P1 receptor agonists and use thereof |
| US8791100B2 (en) * | 2010-02-02 | 2014-07-29 | Novartis Ag | Aryl benzylamine compounds |
| EP2643303A1 (en) | 2010-11-24 | 2013-10-02 | Allergan, Inc. | Modulators of s1p receptors |
| FR3017867A1 (fr) * | 2014-02-21 | 2015-08-28 | Inventiva | Nouveaux composes de type phenylazetidine carboxylate ou carboxamide |
| US9718771B2 (en) | 2014-02-28 | 2017-08-01 | Kissei Pharmaceutical Co., Ltd. | Aniline derivative, pharmaceutical composition containing same, and use thereof |
| US9895324B2 (en) | 2014-03-26 | 2018-02-20 | University Of Kentucky Research Foundation | Halogenated diarylacetylenes and methods of treating cancer |
| WO2017070089A1 (en) | 2015-10-19 | 2017-04-27 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| ES2928856T3 (es) | 2015-11-19 | 2022-11-23 | Incyte Corp | Compuestos heterocíclicos como inmunomoduladores |
| WO2017106634A1 (en) | 2015-12-17 | 2017-06-22 | Incyte Corporation | N-phenyl-pyridine-2-carboxamide derivatives and their use as pd-1/pd-l1 protein/protein interaction modulators |
| TWI850624B (zh) | 2015-12-22 | 2024-08-01 | 美商英塞特公司 | 作為免疫調節劑之雜環化合物 |
| ES2906460T3 (es) | 2016-05-06 | 2022-04-18 | Incyte Corp | Compuestos heterocíclicos como inmunomoduladores |
| TW201808902A (zh) | 2016-05-26 | 2018-03-16 | 美商英塞特公司 | 作為免疫調節劑之雜環化合物 |
| PT3472167T (pt) | 2016-06-20 | 2022-11-11 | Incyte Corp | Compostos heterocíclicos como imunomoduladores |
| US20180016260A1 (en) | 2016-07-14 | 2018-01-18 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| MA46045A (fr) | 2016-08-29 | 2021-04-28 | Incyte Corp | Composés hétérocycliques utilisés comme immunomodulateurs |
| EP3558973B1 (en) | 2016-12-22 | 2021-09-15 | Incyte Corporation | Pyridine derivatives as immunomodulators |
| RS63710B1 (sr) | 2016-12-22 | 2022-11-30 | Incyte Corp | Derivati tetrahidro imidazo[4,5-c] piridina kao induktori internalizacije pd-l1 |
| JP7101678B2 (ja) | 2016-12-22 | 2022-07-15 | インサイト・コーポレイション | 免疫調節剤としての複素環式化合物 |
| US20180179201A1 (en) | 2016-12-22 | 2018-06-28 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| TW201835049A (zh) | 2016-12-22 | 2018-10-01 | 美商英塞特公司 | 作為免疫調節劑之雜環化合物 |
| RS66699B1 (sr) | 2018-03-30 | 2025-05-30 | Incyte Corp | Heterociklična jedinjenja kao imunomodulatori |
| TW202425987A (zh) | 2018-05-11 | 2024-07-01 | 美商英塞特公司 | 作為免疫調節劑之雜環化合物 |
| TW202115059A (zh) | 2019-08-09 | 2021-04-16 | 美商英塞特公司 | Ｐｄ—１／ｐｄ—ｌ１抑制劑之鹽 |
| JP7559059B2 (ja) | 2019-09-30 | 2024-10-01 | インサイト・コーポレイション | 免疫調節剤としてのピリド［３，２－ｄ］ピリミジン化合物 |
| PH12022551136A1 (en) | 2019-11-11 | 2023-10-09 | Incyte Corp | Salts and crystalline forms of a pd-1/pd-l1 inhibitor |
| TW202233615A (zh) | 2020-11-06 | 2022-09-01 | 美商英塞特公司 | Ｐｄ—１／ｐｄ—ｌ１抑制劑之結晶形式 |
| TW202233616A (zh) | 2020-11-06 | 2022-09-01 | 美商英塞特公司 | 用於製備ｐｄ－１／ｐｄ－ｌ１抑制劑以及其鹽及結晶形式之方法 |
| US11780836B2 (en) | 2020-11-06 | 2023-10-10 | Incyte Corporation | Process of preparing a PD-1/PD-L1 inhibitor |
| CN113332435B (zh) * | 2021-06-18 | 2022-10-18 | 广州中医药大学(广州中医药研究院) | 鞘氨醇-1-磷酸4受体激动剂及其与真武汤联合在制备治疗慢性肾小球肾炎药物中的应用 |
| AR126733A1 (es) | 2021-08-10 | 2023-11-08 | Abbvie Inc | Inhibidores de nicotinamida ripk1 |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3329781A (en) | 1965-07-06 | 1967-07-04 | Mallory & Co Inc P R | Sequential timing device |
| US4767896A (en) | 1985-09-03 | 1988-08-30 | Molex Incorporated | Stamped circuitry assembly |
| JP2657324B2 (ja) * | 1989-04-19 | 1997-09-24 | 大塚製薬株式会社 | ヘテロ環を有するフェニルカルボン酸誘導体 |
| HUT63941A (en) * | 1992-05-15 | 1993-11-29 | Hoechst Ag | Process for producing 4-alkyl-substituted pyrimidine-5-carboxanilide derivatives, and fungicidal compositions comprising same |
| SK94393A3 (en) | 1992-09-11 | 1994-08-10 | Thomae Gmbh Dr K | Cyclic derivatives of urea, process for their production and their pharmaceutical agents with the content of those |
| EP0650961B1 (de) * | 1993-11-02 | 1997-03-05 | Hoechst Aktiengesellschaft | Substituierte heterocyclische Carbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel |
| DE4405378A1 (de) | 1994-02-19 | 1995-08-24 | Merck Patent Gmbh | Adhäsionsrezeptor-Antagonisten |
| AU2792097A (en) * | 1996-05-24 | 1998-01-05 | Ono Pharmaceutical Co. Ltd. | Phenylsulfonamide derivatives |
| JPH10204059A (ja) | 1997-01-22 | 1998-08-04 | Ono Pharmaceut Co Ltd | フェニルスルホンアミド誘導体 |
| JP3802653B2 (ja) | 1997-05-21 | 2006-07-26 | オリンパス株式会社 | 立体画像表示装置 |
| US6384061B1 (en) | 1997-07-26 | 2002-05-07 | Lg Chemical Ltd. | Hydantoin compounds and methods related thereto |
| ID26773A (id) * | 1998-07-08 | 2001-02-08 | Aventis Pharma Gmbh | Sulfur tersubstitusi pada asam sulfonilaminokarboksilat n-arilamida, persiapan, penggunaan dan persiapan pembuatan obat yang menyertainya |
| WO2000031536A2 (en) * | 1998-11-23 | 2000-06-02 | President And Fellows Of Harvard College | Detecting structural or synthetic information about chemical compounds |
| AU2002237988B2 (en) | 2001-01-30 | 2008-01-03 | University Of Virginia Patent Foundation | Agonists and antagonists of sphingosine-1-phosphate receptors |
| MXPA01013326A (es) | 2001-02-14 | 2002-08-26 | Warner Lambert Co | Bifenil sulfonamidas utiles como inhibisdores de metaloproteinasa de matriz. |
| US20020183519A1 (en) | 2001-03-13 | 2002-12-05 | Herbert Nar | Antithrombotic carboxylic acid amides |
| CA2472680A1 (en) | 2002-01-18 | 2003-07-31 | Merck & Co., Inc. | Selective s1p1/edg1 receptor agonists |
| US20050113283A1 (en) | 2002-01-18 | 2005-05-26 | David Solow-Cordero | Methods of treating conditions associated with an EDG-4 receptor |
| EP1470137B1 (en) * | 2002-01-18 | 2009-09-02 | Merck & Co., Inc. | Edg receptor agonists |
| AU2003276043A1 (en) | 2002-06-17 | 2003-12-31 | Merck & Co., Inc. | 1-((5-aryl-1,2,4-oxadiazol-3-yl)benzyl)azetidine-3-carboxylates and 1-((5-aryl-1,2,4-oxadiazol-3-yl)benzyl)pyrrolidine-3-carboxylates as edg receptor agonists |
| UA79300C2 (en) * | 2002-08-12 | 2007-06-11 | Janssen Pharmaceutica Nv | N-aryl piperidine substituted biphenylcarboxamides as inhibitors of apolipoprotein b secretion |
| TW200408393A (en) | 2002-10-03 | 2004-06-01 | Ono Pharmaceutical Co | Antagonist of lysophosphatidine acid receptor |
| AU2003298611A1 (en) | 2002-11-21 | 2004-06-18 | Eli Lilly And Company | Mixed lineage kinase modulators |
| DE10300398A1 (de) | 2003-01-09 | 2004-07-22 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verwendung von substituierten 2-Phenylbenzimidazolen als Arzneimittel |
| ES2467160T3 (es) | 2003-05-19 | 2014-06-12 | Irm Llc | Compuestos y composiciones inmunosupresores |
| JP4728962B2 (ja) | 2003-05-19 | 2011-07-20 | アイアールエム・リミテッド・ライアビリティ・カンパニー | 免疫抑制化合物および組成物 |
| US7723376B2 (en) * | 2003-07-15 | 2010-05-25 | Korea Research Institute Of Bioscience And Biotechnology | 2-oxo-heterocyclic compounds and pharmaceutical compositions |
| WO2005020882A2 (ja) | 2003-08-29 | 2005-03-10 | Ono Pharmaceutical Co | Ｓ１ｐ受容体結合能を有する化合物およびその医薬用途 |
| WO2006020951A1 (en) | 2004-08-13 | 2006-02-23 | Praecis Pharmaceuticals, Inc. | Methods and compositions for modulating sphingosine-1-phosphate (s1p) receptor activity |
| US20060223866A1 (en) * | 2004-08-13 | 2006-10-05 | Praecis Pharmaceuticals, Inc. | Methods and compositions for modulating sphingosine-1-phosphate (S1P) receptor activity |
| DK1650186T3 (da) * | 2004-10-22 | 2008-10-13 | Sun Pharmaceutical Ind Ltd | Nye dicarboxylsyrederivater |
| ES2378776T3 (es) | 2004-12-13 | 2012-04-17 | Ono Pharmaceutical Co., Ltd. | Derivado de ácido aminocarboxílico y uso medicinal del mismo |
| JP2007051121A (ja) * | 2005-07-22 | 2007-03-01 | Taiho Yakuhin Kogyo Kk | プロスタグランジンｄ合成酵素を阻害するピリミジン化合物 |
| CA2630714C (en) | 2005-11-23 | 2014-01-14 | Epix Delaware, Inc. | S1p receptor modulating compounds and use thereof |
| US7919519B2 (en) * | 2005-11-23 | 2011-04-05 | Epix Pharmaceuticals Inc. | S1P receptor modulating compounds and use thereof |
| US7790707B2 (en) | 2006-03-21 | 2010-09-07 | Epix Pharmaceuticals Inc. | S1P receptor modulating compounds and use thereof |
| JP5191497B2 (ja) | 2007-03-21 | 2013-05-08 | エピックス ファーマシューティカルズ，インコーポレイテッド | Ｓ１ｐ受容体調節化合物およびその使用 |
| KR20100051849A (ko) * | 2007-08-08 | 2010-05-18 | 메르크 세로노 에스. 에이. | 다발성 경화증의 치료를 위한 스핑고신-1-포스페이트(ｓ1ｐ)수용체에 결합하는 6-아미노-피리미딘-4-카르복스아미드 유도체 및 이와 관련된 화합물 |
| US8080542B2 (en) | 2007-09-20 | 2011-12-20 | Amgen, Inc. | S1P receptor modulating compounds and use thereof |
| US7939546B2 (en) * | 2007-10-12 | 2011-05-10 | Supergen, Inc. | Quinoline derivatives for modulating DNA methylation |
-
2008
- 2008-09-19 US US12/234,514 patent/US8080542B2/en not_active Expired - Fee Related
- 2008-09-19 EP EP08831946A patent/EP2188252B1/en active Active
- 2008-09-19 ES ES08831946T patent/ES2360929T3/es active Active
- 2008-09-19 JP JP2010525834A patent/JP2010540438A/ja active Pending
- 2008-09-19 WO PCT/US2008/010887 patent/WO2009038759A2/en not_active Ceased
- 2008-09-19 DE DE602008006209T patent/DE602008006209D1/de active Active
- 2008-09-19 AT AT08831946T patent/ATE505454T1/de not_active IP Right Cessation
- 2008-09-19 AU AU2008302746A patent/AU2008302746B2/en not_active Ceased
- 2008-09-19 MX MX2010002885A patent/MX2010002885A/es active IP Right Grant
- 2008-09-19 CA CA2699417A patent/CA2699417A1/en not_active Abandoned
-
2011
- 2011-12-16 US US13/327,951 patent/US20120088749A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP2010540438A (ja) | 2010-12-24 |
| AU2008302746A1 (en) | 2009-03-26 |
| US8080542B2 (en) | 2011-12-20 |
| EP2188252B1 (en) | 2011-04-13 |
| AU2008302746B2 (en) | 2014-07-03 |
| EP2188252A2 (en) | 2010-05-26 |
| DE602008006209D1 (de) | 2011-05-26 |
| ATE505454T1 (de) | 2011-04-15 |
| US20120088749A1 (en) | 2012-04-12 |
| US20090082331A1 (en) | 2009-03-26 |
| CA2699417A1 (en) | 2009-03-26 |
| WO2009038759A3 (en) | 2009-07-23 |
| ES2360929T3 (es) | 2011-06-10 |
| WO2009038759A2 (en) | 2009-03-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2010002885A (es) | Derivados de acido 1-(4-(bencilbenzamido)-bencil)-azetidin-3-carbo xilico y compuestos relacionados como moduladores de receptores de s1p para el tratamiento de trastornos inmunitarios. | |
| MX2009010060A (es) | Compuestos moduladores del receptor de esfingosin-1-fosfato y uso de los mismos. | |
| WO2007061458A3 (en) | S1p receptor modulating compounds and use thereof | |
| SI1814878T1 (sl) | Spojine spiro-2,4-pirimidindiamina in njihova uporaba | |
| ZA202103231B (en) | Pyridazinone compounds and uses thereof | |
| PH12014502333A1 (en) | Anti-baff-anti-il-17 bispecific antibodies | |
| PH12016500939A1 (en) | Methods of treatment using selective bcl-2 inhibitors | |
| GEP20207147B (en) | Substituted 3-azabicyclo[3.1.0]hexanes as ketohexokinase inhibitors | |
| SMT202300355T1 (it) | Composti di piridazinone e loro usi | |
| RU2015131629A (ru) | Магнитный тонер | |
| GEAP201814268A (en) | Diacylglycerol acyltransferase 2 inhibitors for use in the treatment of metabolic and related disorders | |
| WO2011150156A3 (en) | Heteroaryl compounds and methods of use thereof | |
| MA32481B1 (fr) | Compositions et procédés d'utilisation pour des anticorps thérapeutiques | |
| NO20100077L (no) | Behandling med alfa7-selektive ligander | |
| HK1258823A1 (zh) | 用於治疗肌营养不良的方法 | |
| MY174182A (en) | Polymer and asphalt composition | |
| MX2021002060A (es) | Inhibidores de la interacción proteína-proteína keap1-nrf2. | |
| Vergelli et al. | 2-Arylacetamido-4-phenylamino-5-substituted pyridazinones as formyl peptide receptors agonists | |
| MX2018000506A (es) | Agentes, usos y metodos para el tratamiento. | |
| MX2017013814A (es) | Composicion de material electricamente conductora. | |
| IN2015DN00345A (enExample) | ||
| MX2019006058A (es) | Granulos de mineral metalico. | |
| WO2008008841A3 (en) | Use of benzimidazole derivatives for the treatment and/or prevention of autoimmune disorders | |
| WO2008134513A3 (en) | Copper lowering treatment of autoimmune diseases | |
| MX2020008984A (es) | Compuestos de ciclohexilo sustituido como inhibidores de nop. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |